Surgical management of breast cancer liver metastases

Maria A. Cassera, Chet W. Hammill, Michael B. Ujiki, Ronald F. Wolf, Lee L. Swanström, Paul D. Hansen

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Introduction: Selected patients with isolated breast cancer liver metastases (BCLM) may benefit from surgical management; however, indications remain unclear and the risks may outweigh the benefits in patients with a generally poor prognosis. Methods: Between 1998 and 2006, 17 patients diagnosed with BCLM were considered for surgical management (<4 tumours, tumour <4 cm in diameter and no/stable extrahepatic metastases). Peri-operative and outcomes data were analysed and compared. Results: Eight patients were found to have extensive or untreatable disease on staging laparoscopy and intra-operative ultrasound (SL/IOUS). The remaining nine patients underwent surgical management [seven laparoscopic radiofrequency ablations (RFA) and two hepatic resections]. Median length of follow-up for patients treated surgically was 40.0 months, median disease-free survival (DFS) was 32.2 months and median time to disease progression was 17.7 months. Of the eight patients not amenable to surgery, median length of follow-up was 21.8 months. Conclusion: SL/IOUS prevented unnecessary laparotomy in half of the patients taken to the operating room for surgical treatment of BCLM. In patients with BCLM, SL/IOUS should be considered standard of care before surgical intervention. The small number of patients and short follow-up may be inadequate to determine the true value of surgical management in this group of patients with BCLM.

Original languageEnglish
Pages (from-to)272-278
Number of pages7
Issue number4
StatePublished - Apr 2011


  • hepatic resection
  • radiofrequency ablation
  • survival


Dive into the research topics of 'Surgical management of breast cancer liver metastases'. Together they form a unique fingerprint.

Cite this